Neil Clark & Shaun Claydon of Destiny Pharma: Significant progress in H1 will continue in 2022 & beyond
Episode 883, Sep 08, 2022, 11:28 AM
Neil Clark CEO & Shaun Claydon, CFO of Destiny Pharma #DEST & reflect on the progress they have made on their late-stage clinical assets in H1 & are confident of further advancement toward major milestones in 2022 and beyond.
Financial highlights
· Cash and short term deposits at 30 June 2022 of £8.4 million (30 June 2021: £7.1 million; 31 December 2021: £4.6 million).
· Net assets of £10.7 million at 30 June 2022 (30 June 2021: £10.2 million; 31 December 2021: £7.5 million).
· Expenditure on R&D in the period of £2.5 million (half-year 2021: £2.0 million; full year 2021: £3.7 million).
· Company funded through to mid-2023.
Operational highlights
NTCD-M3 for the prevention of C. difficile infection (CDI) recurrence
· Finalising preparations for the pivotal Phase 3 clinical trial of NTCD-M3 and good progress made on partner discussions to help co-fund studies and lead commercialisation.
· Positive scientific advice received from European Medicines Agency (EMA) on proposed Phase 3 study design.
· US and European market research confirms substantial market opportunity for NTCD-M3.
· Results from US research support the use of NTCD-M3 following all commonly used antibiotic treatments.
· Positive new data published on the absence of toxic gene transfer to NTCD-M3 in the peer-reviewed journal, Public Library of Science One (PLOS ONE).
XF-73 Nasal for the prevention of post-surgical infections
· US Food and Drug Administration (FDA) has clarified Phase 3 and US registration pathway for XF-73 Nasal gel for the prevention of post-surgical staphylococcal infections.
· EMA feedback on XF-73 Nasal gel Phase 3 programme identifies a clear route through European approval as a ground-breaking hospital infection prevention product.
· Global Phase 3 study design progressing following discussions with regulators and key opinion leaders.
· External European market research reports show that XF-73 Nasal gel is seen as a very promising alternative to the current standard of treatment, mupirocin, by both clinicians and payers. The study suggests XF-73 has the potential to replace the current standard of treatment as the preferred pre-surgical nasal decolonisation agent.
To read the full RNS click here
Financial highlights
· Cash and short term deposits at 30 June 2022 of £8.4 million (30 June 2021: £7.1 million; 31 December 2021: £4.6 million).
· Net assets of £10.7 million at 30 June 2022 (30 June 2021: £10.2 million; 31 December 2021: £7.5 million).
· Expenditure on R&D in the period of £2.5 million (half-year 2021: £2.0 million; full year 2021: £3.7 million).
· Company funded through to mid-2023.
Operational highlights
NTCD-M3 for the prevention of C. difficile infection (CDI) recurrence
· Finalising preparations for the pivotal Phase 3 clinical trial of NTCD-M3 and good progress made on partner discussions to help co-fund studies and lead commercialisation.
· Positive scientific advice received from European Medicines Agency (EMA) on proposed Phase 3 study design.
· US and European market research confirms substantial market opportunity for NTCD-M3.
· Results from US research support the use of NTCD-M3 following all commonly used antibiotic treatments.
· Positive new data published on the absence of toxic gene transfer to NTCD-M3 in the peer-reviewed journal, Public Library of Science One (PLOS ONE).
XF-73 Nasal for the prevention of post-surgical infections
· US Food and Drug Administration (FDA) has clarified Phase 3 and US registration pathway for XF-73 Nasal gel for the prevention of post-surgical staphylococcal infections.
· EMA feedback on XF-73 Nasal gel Phase 3 programme identifies a clear route through European approval as a ground-breaking hospital infection prevention product.
· Global Phase 3 study design progressing following discussions with regulators and key opinion leaders.
· External European market research reports show that XF-73 Nasal gel is seen as a very promising alternative to the current standard of treatment, mupirocin, by both clinicians and payers. The study suggests XF-73 has the potential to replace the current standard of treatment as the preferred pre-surgical nasal decolonisation agent.
To read the full RNS click here